Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877767 | 0.86 | LMNA (0.64) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL8132638 | 0.85 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| Bromide SCHEMBL9690249 | 0.81 | RAB9A (0.59) | LMNANPSR1RAB9AALDH1A1POLB | |
| SCHEMBL9377652 | 0.81 | LMNA (0.55) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL19596918 | 0.79 | GLS (0.72) | LMNANPSR1ALDH1A1POLBTSHR | |
| SCHEMBL24000166 | 0.78 | ALDH1A1 (0.65) | LMNANPSR1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL10109757 | 0.78 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL6885992 | 0.78 | LMNA (0.77) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12862543 | 0.78 | LMNA (0.59) | LMNANPSR1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12892245 | 0.78 | LMNA (0.71) | LMNANPSR1RAB9AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-7754773-B2 | Composition and synthesis of new reagents for inhibition of HIV replication | UNIVERSITY OF MASSACHUSETTS (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053181-A1 | PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | LMNA 1826/4885NPSR1 79/4885RAB9A 1388/4885 |
| US-20070099919-A1 | Composition and synthesis of new reagents for inhibition of HIV replication | REV1, MAVS, ISG15 | LMNA 2874/4885NPSR1 4582/4885RAB9A 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.